Describing and characterising variability in ALS disease progression

References

• Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. How common are ALS plateaus and reversals? Neurology 2016;186:808–12.
   Google Scholar
• Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, Laird AS, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med. 2012;18:1418–22.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA). Amyotrophic lateral sclerosis: developing drugs for treatment guidance for industry.
   Google Scholar
• Küffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51–7.
   PubMed Web of Science ®Google Scholar
• Ong ML, Tan PF, Holbrook JD. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS One. 2017;12:e0174925.
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719–25.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• The Amyotrophic Lateral Sclerosis Functional Rating Scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996;53:141–7.
   PubMed Web of Science ®Google Scholar
• Stubendorff B, Grehl T, Neuwirth C, Rödiger A, Gunkel A, Radscheidt M, et al. P 48 The time of the ALSFRS-R to decrease to 50% (D50) in a sigmoidal decay model sufficiently describes the complete disease course of amyotrophic lateral sclerosis. Clin Neurophysiol. 2017;128:e353–4–e354.
   Google Scholar
• Steinacker P, Huss A, Mayer B, Grehl T, Grosskreutz J, Borck G, et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:112–9.
   PubMed Web of Science ®Google Scholar
• Huber RG, Pandey S, Chhangani D, Rincon-Limas DE, Staff NP, Yeo CJJ. Identification of potential pathways and biomarkers linked to progression in ALS. Ann Clin Transl Neurol. 2023;10:150–65. 10.1002/acn3.51697
   PubMed Web of Science ®Google Scholar
• Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481–8.
   PubMed Web of Science ®Google Scholar
• Chen T, Guestrin C. XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining [Internet]. San Francisco California USA: ACM; 2016:785–94 [cited 2022 Nov 4]. Available at: 10.1145/2939672.2939785
   Google Scholar
• Ramaneswaran S, Srinivasan K, Vincent PMDR, Chang CY. Hybrid inception v3 XGBoost Model for acute lymphoblastic leukemia classification. Comput Math Methods Med. 2021;2021:e2577375–10.
   Web of Science ®Google Scholar
• Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713–7.
   PubMed Web of Science ®Google Scholar
• Vasta R, D'Ovidio F, Canosa A, Manera U, Torrieri MC, Grassano M, et al. Plateaus in amyotrophic lateral sclerosis progression: results from a population-based cohort. Eur J Neurol. 2020;27:1397–404.
   PubMedGoogle Scholar
• Hu N, Shen D, Yang X, Cui L, Liu M. Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis. J Clin Neurosci. 2022;97:93–8.
   PubMed Web of Science ®Google Scholar
• Bakker LA, Schröder CD, Tan HHG, Vugts SMAG, van Eijk RPA, van Es MA, et al. Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R. J Neurol Neurosurg Psychiatry. 2020;91:75–81.
   PubMed Web of Science ®Google Scholar
• Baldinger R, Katzberg HD, Weber M. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012:CD004157.
   Google Scholar
• Krarup C. Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis. Clin Neurophysiol. 2011;122:414–22.
   PubMed Web of Science ®Google Scholar
• Jacobsen AB, Bostock H, Tankisi H. Following disease progression in motor neuron disorders with 3 motor unit number estimation methods. Muscle Nerve. 2019;59:82–7.
   PubMed Web of Science ®Google Scholar
• Bruneteau G, Simonet T, Bauché S, Mandjee N, Malfatti E, Girard E, et al. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain. 2013;136:2359–68.
   PubMed Web of Science ®Google Scholar
• Jagtap SA, Kuruvilla A, Govind P, Nair MD, Sarada C, Varma RP. Multipoint incremental motor unit number estimation versus amyotrophic lateral sclerosis functional rating scale and the medical research council sum score as an outcome measure in amyotrophic lateral sclerosis. Ann Indian Acad Neurol. 2014;17:336–9.
   PubMed Web of Science ®Google Scholar
• Liu XX, Zhang J, Zheng JY, Zhang S, Xu YS, Kang DX, et al. Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2009;39:304–9.
   PubMed Web of Science ®Google Scholar
• Johnson SA, Burke KM, Scheier ZA, Keegan MA, Clark AP, Chan J, et al. Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis. Muscle Nerve. 2022;66:495–502.
   PubMedGoogle Scholar
• Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C, et al. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol. 2014;76:643–57.
   PubMed Web of Science ®Google Scholar
• Gomeni R, Fava M, Pooled Resource Open-Access ALS Clinical Trials Consortium. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:119–29.
   PubMed Web of Science ®Google Scholar
• Hothorn T, Jung HH. RandomForest4Life: a Random Forest for predicting ALS disease progression. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:444–52.
   PubMed Web of Science ®Google Scholar
• Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–33.
   PubMed Web of Science ®Google Scholar
• Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009;326:1549–54.
   PubMed Web of Science ®Google Scholar
• Mancuso R, Martínez-Muriana A, Leiva T, Gregorio D, Ariza L, Morell M, et al. Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1(G93A) ALS mice and after partial muscle denervation. Neurobiol Dis. 2016;95:168–78.
   PubMed Web of Science ®Google Scholar
• Garuti G, Rao F, Ribuffo V, Sansone VA. Sialorrhea in patients with ALS: current treatment options. DNND. 2019;9:19–26.
   Google Scholar
• Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. Neurology. 2004;63:1364–70.
   PubMed Web of Science ®Google Scholar
• Gunes T, Sirin NG, Sahin S, Kose E, Isak B. Use of CMAP, MScan fit-MUNE, and MUNIX in understanding neurodegeneration pattern of ALS and detection of early motor neuron loss in daily practice. Neurosci Lett. 2021;741:135488.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258:613–7.
   PubMed Web of Science ®Google Scholar